Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1–High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial

Byoung Chul Cho, Jong Seok Lee, Yi Long Wu, Irfan Cicin, Manuel Cobo Dols, Myung Ju Ahn, Kristof Cuppens, Rémi Veillon, Ernest Nadal, Josiane Mourão Dias, Claudio Martin, Martin Reck, Edward B. Garon, Enriqueta Felip, Luis Paz-Ares, Francoise Mornex, Everett E. Vokes, Alex A. Adjei, Clifford Robinson, Masashi SatoYulia Vugmeyster, Andreas Machl, Francois Audhuy, Surendra Chaudhary, Fabrice Barlesi

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1–High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial'. Together they form a unique fingerprint.

Medicine & Life Sciences